Literature DB >> 12038777

New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells.

P Valent1, M Baghestanian, H C Bankl, C Sillaber, W R Sperr, J Wojta, B R Binder, K Lechner.   

Abstract

Venous thromboembolism represents a significant cause of morbidity worldwide. The factors that underly thrombophilia are manifold. The concept of Virchow defines the well known triad of stasis, humoral factors, and pathologies of the vascular wall. In the current article, an additional factor, the "accumulation of repair cells" is discussed. This novel concept highlights the mast cell that accumulates around thrombosed vessels and provides a number of important repair molecules including heparin, profibrinolytic tPA, and fibrinogenolytic beta-tryptase. Thus, mast cell recruitment and activation may result in local thrombolysis and prevention of coagulation. In line with this concept, mast cell-deficient mice are more susceptible to lethal thrombogenic stimuli compared to normal mice. The factors (cytokines) that trigger mast cell accumulation and release of repair molecules have also been identified - the most important one appears to be stem cell factor (SCF). All in all. our novel concept suggests that the patho-physiology of thrombosis may involve a "physiologic" cell that provides the same repair molecules that are used for treatment of thrombotic disorders by the physician. Whether an altered availability of components of this cellular repair system can predispose for thrombophilia remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12038777

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  Mast cell tryptase deficiency attenuates mouse abdominal aortic aneurysm formation.

Authors:  Jie Zhang; Jiusong Sun; Jes S Lindholt; Galina K Sukhova; Mark Sinnamon; Richard L Stevens; Roberto Adachi; Peter Libby; Robert W Thompson; Guo-Ping Shi
Journal:  Circ Res       Date:  2011-04-14       Impact factor: 17.367

2.  Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner.

Authors:  Junru Wang; Junying Zheng; Ashwini Kulkarni; Wen Wang; Sarita Garg; Paul L Prather; Martin Hauer-Jensen
Journal:  Dig Dis Sci       Date:  2014-05-22       Impact factor: 3.199

Review 3.  Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Authors:  Peter Valent; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang Füreder; Gerit-Holger Schernthaner; Wolfgang R Sperr; Rudolf Kirchmair; Dominik Wolf
Journal:  Leuk Res       Date:  2017-05-12       Impact factor: 3.156

Review 4.  Physiological and pathophysiological functions of intestinal mast cells.

Authors:  Stephan C Bischoff
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

5.  Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib.

Authors:  Tilde Kristensen; Else Randers; Jesper Stentoft
Journal:  Leuk Res Rep       Date:  2012-11-10

6.  Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.

Authors:  Sabine Cerny-Reiterer; Anja Rabenhorst; Gabriele Stefanzl; Susanne Herndlhofer; Gregor Hoermann; Leonhard Müllauer; Sigrid Baumgartner; Christine Beham-Schmid; Wolfgang R Sperr; Christine Mannhalter; Heinz Sill; Werner Linkesch; Michel Arock; Karin Hartmann; Peter Valent
Journal:  Oncotarget       Date:  2015-02-20

Review 7.  Mast Cell Chymase and Kidney Disease.

Authors:  Shamila Vibhushan; Manuela Bratti; Juan Eduardo Montero-Hernández; Alaa El Ghoneimi; Marc Benhamou; Nicolas Charles; Eric Daugas; Ulrich Blank
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

Review 8.  Mast cells in vulnerable atherosclerotic plaques--a view to a kill.

Authors:  Ken A Lindstedt; Mikko I Mäyränpää; Petri T Kovanen
Journal:  J Cell Mol Med       Date:  2007 Jul-Aug       Impact factor: 5.310

Review 9.  Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.

Authors:  Frank M P van Haren; Clive Page; John G Laffey; Antonio Artigas; Marta Camprubi-Rimblas; Quentin Nunes; Roger Smith; Janis Shute; Mary Carroll; Julia Tree; Miles Carroll; Dave Singh; Tom Wilkinson; Barry Dixon
Journal:  Crit Care       Date:  2020-07-22       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.